Cover Image
市場調查報告書

神經調節設備、植入式輸液幫浦的全球市場:2016年

2016 Global Markets For Neuromodulation Devices And Implantable Infusion Pumps

出版商 Life Science Intelligence, Inc. 商品編碼 348204
出版日期 內容資訊 英文 103 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經調節設備、植入式輸液幫浦的全球市場:2016年 2016 Global Markets For Neuromodulation Devices And Implantable Infusion Pumps
出版日期: 2016年03月26日 內容資訊: 英文 103 Pages
簡介

今後5年,愈來愈多患者將受到利用神經調節設備的恩惠。2015年的該市場規模估計達46億美元,不過,今後由於可使用神經調節設備的適應症的擴大和的對到目前為止未利用患者人口的引進擴大等,預計將更推動成長。

本報告提供全球神經調節設備及植入式輸液幫浦的市場相關調查,主要的產品、企業概要,各主要的地區/國家、產品種類的治療數量及市場規模的變化與預測,以及主要企業的簡介等彙整。

第1章 摘要整理

  • 美國
  • 歐洲
  • 亞太地區、其他地區
  • 競爭分析

第2章 產品、企業

  • 神經調節設備
    • 腦深部刺激
    • 感音性聽障的耳蝸、中耳植入式助聽器
    • 腸胃刺激
    • 阻塞型睡眠呼吸中止症症候群的舌下神經刺激
    • 視網膜刺激
    • 薦骨神經
    • 脊髓
    • 三叉神經
    • 迷走神經
    • 新的神經刺激標的
  • 植入式輸液幫浦

第3章 神經刺激&植入式輸液幫浦:全球市場分析

  • 神經調節設備的裝置數量、市場預測:各地區
    • 美國
      • 疼痛治療的脊髓刺激
      • 感音性聽障
      • 消化器官、泌尿系統
      • 癲癇
      • 腦深部刺激
      • 阻塞型睡眠呼吸中止症症候群
      • 競爭分析
    • 歐洲
      • 疼痛治療的脊髓刺激
      • 感音性聽障
      • 消化器官、泌尿系統
      • 癲癇
      • 腦深部刺激
      • 阻塞型睡眠呼吸中止症症候群
      • 血性心臟衰竭
    • 亞太地區、其他地區
      • 疼痛治療的脊髓刺激
      • 感音性聽障
      • 消化器官、泌尿系統
      • 癲癇
      • 腦深部刺激
    • 美國之外的市場競爭分析
  • 植入式輸液幫浦的治療數量、市場預測:各地區

第4章 調查對象企業

  • Advanced Bionics/Sonova
  • Boston Scientific
  • Cerbomed
  • CerebralRx
  • Cochlear
  • Codman & Shurtleff (Johnson & Johnson)
  • Flowonix Medical
  • ImThera
  • Inspire Medical Systems
  • LivaNova
  • MED-EL
  • Medtronic
  • Neurelec
  • Neuronetics
  • NeuroPace
  • NeuroSigma
  • Nurotron
  • St. Jude Medical

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

A rising number of patients is expected to benefit from the use of neuromodulation devices in the next 5 years according to LSI's new analysis, "Global Markets for Neuromodulation Devices and Implantable Infusion Pumps in 2016." The report discusses the major forces affecting growth in the markets for implantable infusion pumps; neuromodulation devices used for established applications such as chronic pain, sensorineural hearing loss, gastroparesis, urinary incontinence, fecal incontinence, epilepsy, major depression, Parkinson's disease, essential tremor, and dystonia; and neuromodulation systems intended for novel uses such as congestive heart failure, obstructive sleep apnea, and vision loss. Expanded indications and the adoption of neuromodulation devices for previously untapped patient populations are expected to drive growth throughout the global market, which was valued at $4.6 billion in 2015. This in-depth analysis provides detailed segmentation for neuromodulation devices and implantable infusion pumps in the U.S., Europe, and the rest of the world.

Benefits of this report:

  • An analysis of the competitive landscape for neuromodulation devices and implantable infusion pumps in the U.S. and international markets;
  • Quantitative metrics including patient populations, the number of systems sold, and revenues; and
  • Detailed forecasts covering the period from 2014-2021.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. The United States
  • 1.2. Europe
  • 1.3. Asia-Pacific and the Rest of the World
  • 1.4. Competitive Analysis
  • Exhibit 1-1: Global Market Forecast for Neuromodulation Devices and Implantable Infusion Pumps, 2014-2021
  • Exhibit 1-2: Global Market Forecast, Neuromodulation Devices and Implantable Infusion Pumps by Region, 2014-2021
  • Exhibit 1-3: U.S. Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021
  • Exhibit 1-4: European Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021
  • Exhibit 1-5: AP & ROW Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021
  • Exhibit 1-6: Global Supplier Shares for Neuromodulation Devices & Implantable Infusion Pumps, 2014 & 2015

2. PRODUCTS AND COMPANIES

  • 2.1. Neuromodulation Devices
    • 2.1.1. Deep Brain Stimulation
    • 2.1.2. Cochlear and Middle Ear Implants for Sensorineural Hearing Loss
    • 2.1.3. Gastrointestinal Stimulation
    • 2.1.4. Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    • 2.1.5. Retinal Stimulation
    • 2.1.6. Sacral Nerve
    • 2.1.7. Spinal Cord
    • 2.1.8. Trigeminal Nerve
    • 2.1.9. Vagus Nerve
    • 2.1.10. Novel Neuromodulation Targets
  • 2.2. Implantable Infusion Pumps
  • Exhibit 2-1: Neuromodulation Devices and Implantable Infusion Pumps
  • Exhibit 2-2: Selected Neuromodulation Devices in 2016
  • Exhibit 2-3: Selected Implantable Infusion Pumps in 2016

3. NEUROMODULATION & IMPLANTABLE INFUSION PUMPS: GLOBAL MARKET ANALYSIS

  • 3.1. Procedure Volumes and Market Forecasts: Neuromodulation Devices by Region
    • 3.1.1. The United States
      • 3.1.1.1. Spinal Cord Stimulation for Pain
      • 3.1.1.2. Sensorineural Hearing Loss
      • 3.1.1.3. Gastroenterological and Urological
      • 3.1.1.4. Epilepsy
      • 3.1.1.5. Deep Brain Stimulation
      • 3.1.1.6. Obstructive Sleep Apnea
      • 3.1.1.7. Competitive Analysis
    • 3.1.2. Europe
      • 3.1.2.1. Spinal Cord Stimulation for Pain
      • 3.1.2.2. Sensorineural Hearing Loss
      • 3.1.2.3. Gastroenterological and Urological
      • 3.1.2.4. Epilepsy
      • 3.1.2.5. Deep Brain Stimulation
      • 3.1.2.6. Obstructive Sleep Apnea
      • 3.1.2.7. Congestive Heart Failure
    • 3.1.3. Asia-Pacific and the Rest of the World
      • 3.1.3.1. Spinal Cord Stimulation for Pain
      • 3.1.3.2. Sensorineural Hearing Loss
      • 3.1.3.3. Gastroenterological and Urological
      • 3.1.3.4. Epilepsy
      • 3.1.3.5. Deep Brain Stimulation
    • 3.1.4. Competitive Analysis for Markets Outside of the U.S.
  • 3.2. Procedure Volumes and Market Forecasts: Implantable Infusion Pumps by Region
  • Exhibit 3-1: Global Market Forecast for Neuromodulation Devices and Implantable Infusion Pumps, 2014-2021
  • Exhibit 3-2: Global Market Forecast, Neuromodulation Devices and Implantable Infusion Pumps by Region, 2014-2021
  • Exhibit 3-3: Global Market Forecast for Neuromodulation Devices by Product Type, 2014-2021
  • Exhibit 3-4: Global Market Forecast for Neuromodulation Devices by Region, 2014-2021
  • Exhibit 3-5: U.S. Market Forecast for Neuromodulation Devices by Product Type, 2014-2021
  • Exhibit 3-6: U.S. Market Forecast for Spinal Cord Stimulation Devices, 2014-2021
  • Exhibit 3-7: U.S. Market Forecast for Sensorineural Hearing Loss Neuromodulation Devices, 2014-2021
  • Exhibit 3-8: U.S. Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021
  • Exhibit 3-9: U.S. Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021
  • Exhibit 3-10: U.S. Market Forecast for Deep Brain Stimulation Devices, 2014-2021
  • Exhibit 3-11: U.S. Market Forecast for Neuromodulation Devices Used for Obstructive Sleep Apnea, 2014-2021
  • Exhibit 3-12: U.S. Supplier Shares for Neuromodulation Devices, 2014 & 2015
  • Exhibit 3-13: European Market Forecast for Neuromodulation Devices by Product Type, 2014-2021
  • Exhibit 3-14: European Market Forecast for Spinal Cord Stimulation Devices, 2014-2021
  • Exhibit 3-15: European Market Forecast for Sensorineural Hearing Loss Neuromodulation Devices, 2014-2021
  • Exhibit 3-16: European Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021
  • Exhibit 3-17: European Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021
  • Exhibit 3-18: European Market Forecast for Deep Brain Stimulation Devices, 2014-2021
  • Exhibit 3-19: European Market Forecast for Neuromodulation Devices Used for Obstructive Sleep Apnea, 2014-2021
  • Exhibit 3-20: European Market Forecast for Neuromodulation Devices Used for Congestive Heart Failure, 2014-2021
  • Exhibit 3-21: AP & ROW Market Forecast for Neuromodulation Devices by Product Type, 2014-2021
  • Exhibit 3-22: AP & ROW Market Forecast for Spinal Cord Stimulation Devices, 2014-2021
  • Exhibit 3-23: AP & ROW Market Forecast for Sensorineural Hear1ing Loss Neuromodulation Devices, 2014-2021
  • Exhibit 3-24: AP & ROW Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021
  • Exhibit 3-25: AP & ROW Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021
  • Exhibit 3-26: AP & ROW Market Forecast for Deep Brain Stimulation Devices, 2014-2021
  • Exhibit 3-27: OUS Supplier Shares for Neuromodulation Devices, 2014 & 2015
  • Exhibit 3-28: Global Market Forecast for Implantable Infusion Pumps by Region, 2014-2021
  • Exhibit 3-29: U.S. Market Forecast for Implantable Infusion Pumps, 2014-2021
  • Exhibit 3-30: U.S. Supplier Shares for Implantable Infusion Pumps, 2014 & 2015
  • Exhibit 3-31: European Market Forecast for Implantable Infusion Pumps, 2014-2021
  • Exhibit 3-32: AP & ROW Market Forecast for Implantable Infusion Pumps, 2014-2021
  • Exhibit 3-33: OUS Supplier Shares for Implantable Infusion Pumps, 2014 & 2015

4. COMPANIES COVERED

*Detailed profiles for companies in bold.

  • 4.1. Advanced Bionics/Sonova
  • 4.2. Boston Scientific
  • 4.3. Cerbomed
  • 4.4. CerebralRx
  • 4.5. Cochlear
  • 4.6. Codman & Shurtleff (Johnson & Johnson)
  • 4.7. Flowonix Medical
  • 4.8. ImThera
  • 4.9. Inspire Medical Systems
  • 4.10. LivaNova
  • 4.11. MED-EL
  • 4.12. Medtronic
  • 4.13. Neurelec
  • 4.14. Neuronetics
  • 4.15. NeuroPace
  • 4.16. NeuroSigma
  • 4.17. Nurotron
  • 4.18. St. Jude Medical
Back to Top